Thieler Law Corp, member of the Investor Attorney Network, is investigating whether certain officers and directors of Portola Pharmaceuticals Inc (NASDAQ: PTLA) violated securities laws in connection with certain financial statements.

The investigation seeks to discover if possible claims on behalf of purchasers of the securities of Portola Pharmaceuticals Inc (NASDAQ: PTLA)  concerning whether a series of statements by Portola Pharmaceuticals Inc regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

On September 5, 2017, Portola revealed that the approval and launch date of its oral anticoagulant Bevyxxa (betrixaban) would be delayed. The Company further stated that its “best estimate” for the timing of the product release is now the first quarter of 2018, or possibility of an even longer delay.

Following this news, NASDAQ: PTLA fell as much as $3.83, or 6.44% on September 6, 2017.

Based in San Francisco, California, and founded in 2003 Portola Pharmaceuticals Inc a biopharmaceutical company, developing and commercializing therapeutics for patients in the areas of thrombosis, other hematologic disorders, and inflammation.

If you purchased shares of Portola Pharmaceuticals Inc (NASDAQ:PTLA) on or before September 5, 2017, you should contact Thieler Law Corp at mail@thielerlaw.com or call +1 (619) 377 - 4324.

Thieler Law Corp

2534 State Street - Suite 406,

San Diego, CA 92101

by

email: mail@thielerlaw.com 

or

telephone at +1 (619) 377 - 4324

or

visit our website http://www.thielerlaw.com/ 

or

Facsimile: +1 (619) 785 – 3185